The Myeloma Beacon » Beacon BreakingNews - Clinical Trial Supports Revlimid As First-Line Therapy For Myeloma

Beacon BreakingNews - Clinical Trial Supports Revlimid As First-Line Therapy For Myeloma

By: Julie Shilane; Published: July 23, 2009 @ 2:02 pm | Comments Disabled

Celgene, the manufacturer of Revlimid ^[1] (lenalidomide), announced today positive results from a Phase 3 clinical trial using Revlimid as first-line therapy for newly diagnosed multiple myeloma patients. Results show that Revlimid in combination with melphalan ^[2] (Alkeran) and prednisone ^[3], followed by continuous Revlimid, significantly improved time to tumor progression.

Check back for further coverage on The Myeloma Beacon ^[4].

Update: Please see The Myeloma Beacon's full coverage ^[5] of Revlimid as a first-line therapy for myeloma.

Article printed from The Myeloma Beacon: https://myelomabeacon.org

URL to article: https://myelomabeacon.org/news/2009/07/23/beacon-breakingnews-clinical-trial-supports-revlimid-as-first-line-therapy-for-myeloma/

URLs in this post:

[1] Revlimid: https://myelomabeacon.org/resources/2008/10/15/revlimid/

[2] melphalan: https://myelomabeacon.org/resources/2008/10/15/melphalan/

[3] prednisone: https://myelomabeacon.org/resources/2008/10/15/prednisone/

[4] The Myeloma Beacon: https://myelomabeacon.org/

[5] full coverage: https://myelomabeacon.org/news/2009/07/24/clinical-trial-supports-revlimid-as-first-line-therapy-for-myeloma/

Click here to print.